NASDAQ:SGHT Sight Sciences (SGHT) Stock Price, News & Analysis $3.27 -0.06 (-1.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.28 +0.00 (+0.15%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sight Sciences Stock (NASDAQ:SGHT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sight Sciences alerts:Sign Up Key Stats Today's Range$3.11▼$3.3450-Day Range$3.20▼$4.3452-Week Range$2.03▼$7.12Volume229,807 shsAverage Volume112,255 shsMarket Capitalization$169.06 millionP/E RatioN/ADividend YieldN/APrice Target$3.93Consensus RatingHold Company Overview Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. Read More Sight Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreSGHT MarketRank™: Sight Sciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 646th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingSight Sciences has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageSight Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Sight Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sight Sciences are expected to grow in the coming year, from ($0.99) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sight Sciences is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sight Sciences is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSight Sciences has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sight Sciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.11% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Sight Sciences has recently decreased by 9.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSight Sciences does not currently pay a dividend.Dividend GrowthSight Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.11% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Sight Sciences has recently decreased by 9.76%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.18 News SentimentSight Sciences has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sight Sciences this week, compared to 3 articles on an average week.Search Interest1 people have searched for SGHT on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $180,017.00 in company stock.Percentage Held by Insiders30.90% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sight Sciences' insider trading history. Receive SGHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SGHT Stock News HeadlinesSight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 4,889 SharesJuly 8, 2025 | insidertrades.comSight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye DiseaseJuly 30 at 7:00 AM | globenewswire.comThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself. | American Alternative (Ad)Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye DiseaseJuly 29, 2025 | globenewswire.comSight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025July 24, 2025 | globenewswire.com7SGHT : The Analyst Verdict: Sight Sciences In The Eyes Of 4...July 15, 2025 | benzinga.comSGHT - Sight Sciences Inc Chart - MorningstarJuly 5, 2025 | morningstar.comMSight Sciences Leads The Pack Of 3 Promising Penny StocksJune 24, 2025 | uk.finance.yahoo.comSee More Headlines SGHT Stock Analysis - Frequently Asked Questions How have SGHT shares performed this year? Sight Sciences' stock was trading at $3.64 at the beginning of 2025. Since then, SGHT shares have decreased by 10.2% and is now trading at $3.27. How were Sight Sciences' earnings last quarter? Sight Sciences, Inc. (NASDAQ:SGHT) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.01. The business had revenue of $17.51 million for the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative net margin of 63.24% and a negative trailing twelve-month return on equity of 54.62%. Read the conference call transcript. When did Sight Sciences IPO? Sight Sciences (SGHT) raised $150 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,980,000 shares at a price of $20.00-$23.00 per share. Who are Sight Sciences' major shareholders? Sight Sciences' top institutional investors include KCK LTD. (8.46%), Palumbo Wealth Management LLC (0.15%), Vanguard Personalized Indexing Management LLC (0.03%) and CWM LLC (0.01%). Insiders that own company stock include Paul Badawi, D1 Capital Partners LP, David Badawi, Staffan Encrantz, Matthew Link, Jeremy B Hayden, Sam Boong Park and Manohar K Raheja. View institutional ownership trends. How do I buy shares of Sight Sciences? Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sight Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sight Sciences investors own include American Water Works (AWK), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/08/2025Today8/01/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:SGHT CIK1531177 Webwww.sightsciences.com Phone877-266-1144FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Price Target for Sight Sciences$3.93 High Price Target$5.00 Low Price Target$3.00 Potential Upside/Downside+20.3%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.51 million Net Margins-63.24% Pretax Margin-62.91% Return on Equity-54.62% Return on Assets-34.92% Debt Debt-to-Equity Ratio0.51 Current Ratio10.47 Quick Ratio9.99 Sales & Book Value Annual Sales$79.87 million Price / Sales2.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book1.90Miscellaneous Outstanding Shares51,700,000Free Float35,722,000Market Cap$169.06 million OptionableOptionable Beta2.45 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:SGHT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sight Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.